

Cumulative Incidence and Risk Factors for Severe Coronavirus Disease 2019 in French People With Cystic Fibrosis

Harriet Corvol, Sandra de Miranda, Clémence Dehillotte, Lydie Lemonnier, Raphael Chiron, Isabelle Danner-Boucher, Rebecca Hamidfar, Véronique Houdouin, Julie Macey, Christophe Marguet, et al.

▶ To cite this version:

Harriet Corvol, Sandra de Miranda, Clémence Dehillotte, Lydie Lemonnier, Raphael Chiron, et al.. Cumulative Incidence and Risk Factors for Severe Coronavirus Disease 2019 in French People With Cystic Fibrosis. Clinical Infectious Diseases, 2022, 75 (12), pp.2135-2144. 10.1093/cid/ciac333 . hal-03827698

HAL Id: hal-03827698 https://hal.science/hal-03827698v1

Submitted on 15 Jul 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 Cumulative Incidence and Risk Factors for Severe COVID-19 in French People with **Cystic Fibrosis** 2 Harriet Corvol^{1,2*}, Sandra de Miranda³, Clémence Dehillotte⁴, Lydie Lemonnier⁴, Raphael 3 Chiron⁵, Isabelle Danner-Boucher⁶, Rebecca Hamidfar⁷, Véronique Houdouin⁸, Julie Macey⁹, 4 Christophe Marguet¹⁰, Marlène Murris-Espin¹¹, Quitterie Reynaud^{12,17}, Philippe Reix¹³, 5 Martine Reynaud Gaubert¹⁴, Astrid Kemgang², and Pierre-Régis Burgel^{15,16,17} on behalf the 6 French Cystic Fibrosis Reference Network study group*** 7 8 9 ***Members of the French Cystic Fibrosis Reference Network study group are listed in the Acknowledgments 10 section. 11 1. Pediatric Respiratory Department and Pediatric CF Center, Assistance Publique Hôpitaux 12 de Paris (APHP), Hôpital Trousseau, Paris, France; 2. Sorbonne Université, Centre de 13 14 Recherche Saint-Antoine, Paris, France; 3. Pulmonology Department and CF Center, Hôpital Foch, Suresnes, France; 4. Association Vaincre la Mucoviscidose, Paris, France; 5. CF 15 Center, Hôpital Arnaud de Villeneuve, CHU de Montpellier, Montpellier, France; 5. 16 Pulmonology Department and Adult CF Center, Institut du Thorax, CHU de Nantes, Nantes, 17 France; 6. CF Center, CHU de Grenoble, Grenoble, France; 7. Pediatric Pulmonology 18 Department and Pediatric CF Center, APHP, Hôpital Robert Debré, Paris, France; 8. 19 Respiratory Medicine and CF Center, CHU de Bordeaux, Bordeaux, France; 9. Pediatric 20 Respiratory Disease and CF Center, CIC Inserm 1404, Inserm U3111, FHU RESPIR, Rouen 21 University Hospital, Rouen, France; 10. CF Center and Service de Pneumologie Pôle des 22 Voies Respiratoires, CHU de Toulouse, Toulouse, France; 11. Internal Medicine Department 23 and adult CF center, Hospices Civils de Lyon, Research on Healthcare Performance 24 © The Author(s) 2022. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model

(https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

1	(RESHAPE), INSERM U1290, Université de Lyon, Lyon, France. 12. Pediatric CF Center,
2	Hospices Civils de Lyon, UMR 5558 CNRS Equipe EMET, Université Claude Bernard Lyon
3	1, Lyon, France. 13. Respiratory Medicine and adult CF center, Assistance Publique
4	Hôpitaux de Marseille, Aix-Marseille Université UM63, Institut de Recherche pour le
5	Développement, Marseille, France. 14. Respiratory Medicine and National Reference CF
6	Center, AP-HP, Hôpital Cochin, Paris, France; 15. Université de Paris, Institut Cochin,
7	Inserm U-1016, Paris, France; 16. ERN-Lung CF Network, Frankfurt, Germany.

- 8
- 9 *Corresponding Author: Harriet Corvol, MD
- 10 Pediatric Respiratory Department and Pediatric CF Center, Hôpital Trousseau
- 11 26 avenue du Dr Netter, 75012 Paris, France
- 12 Email: <u>harriet.corvol@aphp.fr</u>
- 13 **Running title:** Severe COVID-19 in Cystic Fibrosis
- 14

1 Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections are
closely monitored in people with cystic fibrosis (pwCF), with a special emphasis on severe
cases. Previous studies used hospitalization rates as proxy for severity.

Methods: We evaluated data from coronavirus disease 2019 (COVID-19) cases diagnosed in
French pwCF followed in one of the 47 French CF center over the first year of the pandemic.
Objective criteria were applied for defining severity (e.g., respiratory failure and/or death).
Data were compared to those from all French pwCF using the French CF Registry.

Results: As of April 30, 2021, 223 pwCF were diagnosed with COVID-19, with higher risks 9 in adults (≥18 years, odds ratio [OR]=2.52, 95% confidence interval [CI]=1.82-3.48) and 10 post-transplant individuals (OR=2.68, 95% CI=1.98-3.63). Sixty (26.9%) patients were 11 hospitalized, with an increased risk in post-transplant individuals (OR=4.74, 95% CI=2.49-12 9.02). In 34 (15%) cases, COVID-19 was considered severe; 28/60 (46.7%) hospitalizations 13 occurred in patients without objective criteria of severity. Severe cases occurred mostly in 14 adults (85.3%) and post-transplant pwCF (61.8%, OR=6.02, 95% CI=2.77-13.06). In non-15 transplanted pwCF, risk factors for severity included low lung function (median ppFEV₁ 16 54.6% vs. 75.1%, OR=1.04, 95% CI=1.01-1.08) and CF-associated diabetes (OR=3.26, 95% 17 CI=1.02-10.4). While most cases recovered without sequelae (n=204, 91.5%), 16 (13%) were 18 followed for possible sequelae, and three post-transplant females died. 19

20 Conclusions: Severe COVID-19 cases occurred infrequently during the first year of the 21 pandemic in French pwCF. Non-transplanted adults with severe respiratory disease or 22 diabetes and post-transplant individuals were at risk for severe COVID-19. Thus, specific 23 preventive measures should be proposed.

24 Keywords: COVID-19; SARS-CoV-2; cystic fibrosis; risk factors; severity

1 Introduction

2 Since its inception in December 2019, the coronavirus disease 2019 (COVID-19) outbreak 3 has changed health concerns and priorities throughout the world. As of January 13, 2022, 4 more than 307 million people had been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and at least 5.49 million individuals have died of this disease 5 worldwide [1]. Cystic fibrosis (CF) affects approximately 7,500 people in France [2] as well 6 as at least 90,000 people worldwide. Lung disease remains the major cause of morbidity and 7 mortality in people with CF (pwCF), with a progressive decline in lung function due to a 8 vicious self-perpetuating cycle of airway infections and inflammation [3, 4]. Among the 9 pathogens infecting the airways in pwCF, viruses contribute substantially to the deterioration 10 11 of respiratory function [5].

Given the serious respiratory complications caused by viral infections, pwCF are expected to have higher risk of severe COVID-19. As such, the impact of SARS-CoV-2 infections on pwCF have been closely monitored worldwide via national and international consortia [6-12]. In France, a prospective observational study involving all 47 CF centers has been ongoing since March 2020, with the primary objective of describing the clinical expression of COVID-19 in French pwCF and identifying factors associated with severe outcomes.

Previous studies have revealed that post-lung transplant pwCF are at an increased risk of 18 developing severe COVID-19 [6-11]. However, severity status has been largely examined 19 using healthcare utilization data. Some of the few studies conducted thus far have defined 20 patients with severe COVID-19 based on hospitalization data only. However, indications for 21 hospitalization may differ among countries due to differences across healthcare systems. 22 23 Moreover, clinical experience suggests that hospitalization practices have evolved since the beginning of the pandemic due to evolving knowledge regarding the management of COVID-24 25 19. In the present study, our goal was to present data on all French pwCF diagnosed with COVID-19 using criteria associated with disease severity rather than with only healthcare
 utilization. These criteria included hospitalization in intensive care unit (ICU), respiratory
 support, severe complications (respiratory as well as non-respiratory) or death.

4 Materials and Methods

Since the first wave of COVID-19 in France in March 2020, all 47 CF centers (which follow 5 over 95% of the 7,500 French pwCF) have been collaborating in conducting a prospective 6 observational study (MR004-2218155) to describe the clinical manifestations of SARS-CoV-7 2 infection in French pwCF [2]. The study was approved by the Institutional Review Board of 8 the French Society for Respiratory Medicine (Société de Pneumologie de Langue Française, 9 #CEPRO_2020-013). All patients received information about the study. In accordance with 10 French laws for observational studies, the requirement for written informed consent was 11 12 waived.

Data for pwCF infected by SARS-CoV-2 were collected in a dedicated CF-COVID registry 13 nested within the French CF registry [2]. Criteria for positive COVID-19 cases include: (i) 14 positive SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) tests 15 conducted via nasopharyngeal swabs, (ii) typical aspects of COVID-19 seen on thoracic high-16 resolution computed tomography (HRCT); and/or (iii) serology positive for anti-N SARS-17 CoV-2 antibodies. Typical HRCT aspects include ground-glass opacities (GGO), 18 consolidation, a bilateral and peripheral distribution of lesions, and a round aspect of lesions 19 [13, 14]. 20

COVID-19 transmission history, clinical, biological, and radiological information, as well as
information on medical evolution were prospectively collected and recorded by the caring
physicians in the dedicated CF-COVID registry nested within the French CF registry as
previously described [6]. The baseline clinical characteristics of SARS-CoV-2 infected pwCF
were compared to those of pwCF not diagnosed with SARS-CoV-2 using 2019 data from the

1 French CF registry [2]. Data from pwCF who developed severe COVID-19 were compared to 2 those with a non-severe infection according to their transplantation status (i.e., non-3 transplanted vs. post-lung transplant pwCF). COVID-19 cases were classified as severe given 4 at least one of the following criteria: hospitalization in ICU, respiratory support (additional oxygen therapy, high-flow nasal cannula oxygen therapy, non-invasive ventilation [BiPAP 5 (bilevel positive airway pressure), CPAP (continuous positive airway pressure)], invasive 6 ventilation, extracorporeal membrane oxygenation [ECMO]), respiratory complications 7 (acute respiratory distress syndrome [ARDS], a decline in the percent of predicted forced 8 expiratory volume in one second $[ppFEV_1] > 20$ in absolute value, large or massive 9 hemoptysis, pneumothorax), severe other complications (myocarditis, encephalopathy, renal 10 11 failure, sepsis, multi-organ dysfunction failure), or death.

12 Continuous data were expressed as medians and range values, while categorical data were 13 expressed as numbers and proportions (%). Descriptive statistics were presented for all the 14 study variables. We used Fisher's exact test to compare categorical and qualitative data and 15 implemented Mann Whitney's non-parametric test to evaluate continuous variables. A P-16 value of less than 5% was interpreted as evidence of a statistically significant difference. The 17 analyses were carried out using SAS 9.4 software (Cary, NC, USA).

18

19 **Results**

20 Incidence

Between March 1, 2020, and April 30, 2021, 223 pwCF were diagnosed as infected by SARS-CoV-2: 186 had positive SARS-CoV-2 RT-PCR tests conducted via nasopharyngeal swabs; two had negative RT-PCR findings but imaging patterns typical of COVID-19 on computed tomography (CT) scans; and 35 had positive SARS-CoV-2 serology. Among pwCF with positive serology, 13 were asymptomatic and were diagnosed by a systematic assessment of SARS-CoV-2 serology, whereas 22 had symptomatic infections that were not
 diagnosed using PCR or CT at the time of infection.

Among the 223 cases, 34 (15%) were considered severe. The majority of the severe cases
occurred in adults (≥18 years, n=29, 85.3%) and in post-transplant individuals (n=21, 61.8%).
Figure 1A shows the evolution in the number of cases per month according to age (adults,
≥18 years vs. children, ≤17 years), transplant status, and nationwide lockdowns (described in

7 Supplementary Data).

8 The testing policy for SARS-CoV-2 in France varied across the first year of the COVID-19 9 outbreak (detailed in **Supplementary Data**). Access to PCR tests was very limited at the 10 beginning of the epidemic and widely expanded as the epidemic progressed. While variations 11 in testing strategies might explain the variation in the total number of diagnosed cases, severe 12 cases among pwCF would have been diagnosed at any time, explaining the lower variation in 13 the number of severe cases across the first year of the COVID-19 pandemic (**Figure 1B**).

14 COVID-19 cases as compared with the overall French CF population

We compared the baseline clinical characteristics of 223 SARS-CoV-2 infected pwCF to 15 those of French pwCF not diagnosed with SARS-CoV-2 using data from the French CF 16 Registry [2]. As shown in Table 1, COVID-19 CF cases were older than the overall CF 17 population and were more frequently post-transplant individuals (all p<0.001). Compared to 18 children, adults with CF were at higher risk at being diagnosed with SARS-CoV-2 infection 19 20 (odds ratio [OR] = 2.52, 95% confidence interval [CI] = 1.82-3.48, p <0.001). The risk of diagnosed SARS-CoV-2 infection was also higher in the post-transplant individuals than in 21 the non-transplanted individuals: 61 were diagnosed among the 853 post-transplant patients 22 23 (7.1%) as compared to 162 cases diagnosed among the 6,071 non-transplanted patients (2.6%) (OR = 2.68, 95% CI = 1.98-3.63, p < 0.001). 24

We found differences in patient characteristics consistent with older age and transplant status,
including lower lung function, a more frequent occurrence of CF-associated diabetes, and of
the use of treatments such as oral corticosteroids, azithromycin, CF transmembrane
conductance regulator (CFTR) modulators (more widely available to adolescents and adults
than children <12 years), and long-term oxygen therapy.</p>

6 Non-transplanted vs. post-transplant cases at infection onset

A comparison of the clinical characteristics of non-transplant *vs.* post-transplant COVID-19 cases at the onset of infection is presented in **Table 2**. The median age of post-transplant pwCF was eight years older than that of non-transplant patients (p<0.0001). Post-transplant pwCF had more frequent CF-associated diabetes and systemic arterial hypertension (p<0.0001), and were more likely to be treated with oral steroids (p<0.0001) and azithromycin (p=0.04).

Clinical symptoms at COVID-19 onset are described in Figure 2. Among the 223 cases, 56 13 (25.1%) remained asymptomatic: 44 diagnosed by positive SARS-CoV-2 RT-PCR performed 14 15 for various reasons (e.g., investigation around a case, systematic testing before traveling), and 13 diagnosed by a systematic assessment of SARS-CoV-2 serology. The remaining 167 cases 16 displayed symptoms quite similar to those described in the general population, which 17 included fever (n=104, 46.6%), fatigue (n=98, 44%), and cough (n=84, 37.6%). Except for 18 severe respiratory symptoms such as dyspnea, respiratory distress, and decreased $ppFEV_1>20$ 19 20 (observed mainly in post-transplant pwCF), there were no differences in symptoms at 21 infection onset between post-transplant and non-transplanted pwCF.

22 Non-transplanted vs. post-lung transplant cases

The evolution and treatments of the evaluated cases are described **in Table 3**. Sixty (26.9%) patients were hospitalized, including 31 of the 61 post-transplant pwCF. Post-transplant individuals were more frequently hospitalized than the non-transplanted patients: 31 of the 61 post-transplant patients (50.8%) vs. 29 out of the 162 non-transplanted patients (17.9%) (OR
 = 4.74, 95% CI = 2.49-9.02, p <0.001).

In 34 cases (15.2%), COVID-19 was considered severe, thus indicating that 28/60 (46.7%)
hospitalizations occurred in patients without criteria for severe SARS-CoV-2 infection. Posttransplant pwCF were more at risk to develop a severe form of COVID-19 than nontransplant patients (i.e., 21 of 61 post-transplant patients [34.4%] and 13 of 162 nontransplanted patients [8.0%]; OR = 6.02, 95% CI = 2.77-13.06, p <0.001).

8 The post-transplant cases not only had more frequent hospitalizations, but also more 9 hospitalizations in the ICU, a longer duration of hospitalization, and a more frequent need for 10 respiratory support, additional IV antibiotics, and systemic corticosteroids (**Table 3**). Only 11 post-transplant pwCF developed acute respiratory distress syndrome on follow-up (ARDS; 12 n=5).

While most cases recovered without short-term sequelae (n=204, 91.5%), 16 (13%) were 13 followed for possible sequelae. Three pwCFs died during the COVID-19 evolution; all were 14 post-lung transplant females. These women were aged 34, 45, and 48 years, had their lung 15 transplant between 2017 and 2018, and were under immunosuppressive drugs (e.g., oral 16 corticosteroids); two had CF-associated diabetes and liver disease. All three patients had 17 relatively preserved lung function, with a $ppFEV_1 > 60$. They were hospitalized in ICU for a 18 median of 27 days (19-72 days) prior to death. They all required high-flow nasal cannula 19 20 oxygen therapy and one required invasive ventilation. Two patients developed ARDS, and the third had massive hemoptysis. All received additional systemic corticosteroids. 21

22 Risk factors for COVID-19 severity

The baseline clinical characteristics of the pwCF who developed severe COVID-19 were compared to those of the non-severe group to examine risk factors associated with severity (**Table 4**). Among the non-transplanted pwCFs, patients with severe SARS-CoV-2 infection had the lowest lung function (median $ppFEV_1 = 54.6\%$ for pwCF with severe infection, 75.1% for pwCF without severe infection, OR=1.04, 95% CI=1.01-1.08) and had more frequent CF-associated diabetes (46.2% of pwCF with severe infection had diabetes as compared to 20.8% of pwCF without severe infection, OR=3.26, 95% CI=1.02-10.4). No differences were observed in the baseline clinical characteristics of post-transplant pwCFaccording to severity. Long-term azithromycin prior to SARS-CoV-2 infection was not associated with severity status.

8

9 **Discussion**

In this national multicenter study, we describe the clinical expression of COVID-19 in 10 French pwCF during the first year of the pandemic. Given the serious respiratory 11 complications caused by viral infections in CF, pwCF are expected to be at a higher risk 12 of COVID-19 as well as at a higher risk of disease severity [5]. However, the number of 13 diagnosed COVID-19 cases in pwCF is rather low, though the risk is increased in adults 14 vs. children similarly to the general population [15, 16]. By originally using objective 15 criteria for defining COVID-19 severity, we showed that risk factors included low lung 16 function and diabetes in non-transplanted pwCF. Post-transplant pwCF were more likely 17 to develop severe COVID-19 in congruence with their immunosuppression status, their 18 older age and their more frequent comorbidities such as diabetes and systemic arterial 19 hypertension. 20

In this study, the severity of COVID-19 acute care was examined based on markers of
clinical severity rather than relying solely on hospitalization rates as a proxy for severity, as
reported by other researchers [6-11]. Hence, COVID-19 was classified as severe when the
patient was hospitalized in ICU, needed respiratory support, developed severe complications,
or died. This might explain why the number of hospitalized pwCF was double that of those

who developed severe COVID-19. Especially at the beginning of the pandemic, some pwCF were hospitalized for fear of the impact of infection on CF disease without markers of clinical severity. Thus, by applying the classification described herein, we demonstrated that the main independent risk factor for severe COVID-19 was lower lung function at the onset of infection in non-transplanted pwCF, as well as post-transplant status. Of note, lung function was not associated with severe COVID-19 in post-transplant patients.

The present results confirm our preliminary report within data obtained during the first wave 7 of the COVID-19 pandemic as well as in international studies [6-11] showing that SARS-8 CoV-2 infections occur infrequently in pwCF (with a cumulative incidence of 3% as of April 9 2021). A recent systematic review showed that the risk of developing a SARS-CoV-2 10 11 infection was not increased in pwCF as compared to the general population, with 339 cases reported among 1,236 pwCF from the European CF Society Patient Registry [17]. Two 12 hypotheses have been proposed to explain these findings: the routine use of hand washing, 13 mask wearing, and physical distancing to prevent human-to-human infection, as well as the 14 younger age of the overall cohort of pwCF as compared to the general population [18]. 15

We observed that children with CF were less likely to be diagnosed with SARS-CoV-2 as 16 compared to adults, a finding comparable to the general population [19]. Only 10% of 17 children with CF and COVID-19 developed severe infections, according to a previous 18 international study conducted during the first wave of the pandemic that showed that children 19 20 had mostly mild disease presentations [20]. Several hypotheses have been proposed to explain the lower incidence of COVID-19 in children. Innate and adaptive responses to 21 SARS-CoV-2 have been suggested as possible protective factors against SARS-CoV-2 22 23 infection [16]. In contrast to adults, children have higher susceptibility to various respiratory viruses, higher rates of closely spaced immunization, and therefore a greater likelihood of 24 stimulated trained immunity. This may provide cross-protection against other viruses through 25

memory cells [21, 22]. Children might also seem less likely to be infected because of their
 higher rates of asymptomatic disease.

3 Our study confirms that severe cases of COVID-19 occur relatively infrequently in pwCF. 4 These data are in marked contrast with previous reports of other respiratory viral infections. For example, the H1N1-influenza pandemic in 2009 led to a statistically significant decline in 5 6 lung function and decreased survival in pwCF [23]. Moreover, RSV and rhinovirus infections are strongly associated with pulmonary exacerbations in pwCF [24, 25]. Several studies have 7 shown that bacterial airway infections (i.e., *Pseudomonas aeruginosa*) are often preceded by 8 viral infections [26]. It was observed in vitro that exposure of CF airway epithelial cells to 9 Pseudomonas aeruginosa enhanced SARS-CoV-2 infectivity [27]. Long-term studies are 10 necessary to fully appreciate the impact of COVID-19 on lung function decline in patients 11 12 with pwCF.

Compared to non-transplanted patients, post-transplant pwCF were more frequently 13 diagnosed as infected and more likely to develop severe COVID-19. In congruence with their 14 immunosuppression status, the post-transplant pwCF were also older and had more 15 comorbidities (e.g., CF-associated diabetes and systemic arterial hypertension). Therefore, 16 these patients required greater utilization of healthcare resources, including more frequent 17 hospitalizations, ICU admissions, a higher necessity for respiratory support, and additional 18 antibiotics and systemic corticosteroids. Only post-transplant individuals developed SARS-19 20 CoV-2-associated ARDS or died. These results agree with those of previous international and national reports [6-11]. Additionally, this severity status might mirror the severe COVID-19 21 evolution described in non-CF immunocompromised patients [28-30]. 22

Azithromycin is often prescribed to pwCF as it reduces pulmonary exacerbations and induces
modest improvements in lung function [31]. Hence, one-third of pwCF from the French
Registry are treated with low-dose long-term azithromycin. Despite the absence of

1 randomized clinical trials supporting its prescription, short courses of azithromycin have been widely used in COVID-19 management in the general population due to their 2 immunomodulatory and antiviral properties [32-34]. We observed that pwCF infected by 3 4 SARS-CoV-2 were more frequently under azithromycin at the onset of infection than the remaining cohort of French pwCF (51.6% of the cases). This may reflect the older age of 5 these cases (vs. causal etiologies). Nevertheless, these findings contradict the assumption that 6 this treatment might prevent infection. Moreover, this result is consistent with a cross-7 sectional study conducted in Spain in patients treated with long-term macrolides for chronic 8 respiratory disease [35]. Indeed, we found no differences in COVID-19 severity between 9 pwCF never treated with azithromycin and those who received this treatment at some point 10 11 during the course of their infection.

This prospective study was conducted through the French CF reference network, thus 12 covering all pediatric and adult CF centers and all transplant centers. Additional study 13 strengths are that the standardized study questionnaire was distributed at the start of the 14 pandemic outbreak and that the study was nested within the French CF Registry. The main 15 limitation of this work is that mild cases may have remained undiagnosed due to the absence 16 of sufficient testing for COVID-19. This limitation might not alter our conclusions, as our 17 main results concerned severe cases that would be unlikely to be missed. Another limitation 18 is small number of severe cases of COVID-19, due to their infrequent occurrence, which 19 20 compelled us to make only univariate associations without possibility of adjustment for confounding factors. 21

22 Conclusions

After one year of the COVID-19 pandemic, we found that the cumulative incidence of COVID-19 remained low in pwCF, probably thanks to the fact that pwCF are acclimated to masks, hand hygiene, and social distancing to limit exposure and avoid infection. Non-

transplanted pwCF appear to have better COVID-19 outcomes than anticipated (i.e., as 1 compared to other respiratory viral infections). However, compared to non-transplanted 2 patients, post-transplant pwCF patients were more frequently diagnosed as infected and more 3 4 likely to develop severe COVID-19. This study highlights the need to pursue preventative strategies, including SARS-CoV-2 vaccinations for pwCF as well as for the general 5 6 population to protect susceptible patients and decrease viral spread. Finally, as the pandemic is still unresolved and new SARS-CoV-2 variants are arising that may result in differential 7 expression of COVID-19, close monitoring of CF cohorts is necessary to fully understand the 8 9 consequences of COVID-19 in pwCF.

10

11 NOTES

Author Contributions: Conceptualization and methodology, H.C, C.L, L.L, A.K, and P.R.B.; data provision: all authors; data interpretation, H. C., C. L., L. L., A. K., and P.R.B.; writing—review and editing, H.C and P.R.B. All authors have read and agreed to the published version of the manuscript.

Acknowledgments: French Cystic Fibrosis Reference Network study group (alphabetical
 order)

Michel ABELY, CHU DE REIMS; Nathalie ALLOU, CHU DE LA REUNION-Félix 18 Guyon; Baptiste ARNOUAT, CHU DE VANNES; Carole BAILLY PICCINI, CHU DE 19 20 NICE; Chantal BELLEGUIC, CHU DE RENNES—Pontchaillou; Tiphaine BIHOUEE, CHU DE NANTES; Yves BILLON, CHU DE NANCY; Stéphanie BUI, CHU DE BORDEAUX— 21 Pellegrin; Pierre-Régis BURGEL, AP-HP-Cochin; Boubou CAMARA, CHU DE 22 GRENOBLE; Marie-Christine HERAUD, CHU DE CLERMONT FERRAND; Raphael 23 CHIRON, CHU DE MONTPELLIER; Emmanuelle COIRIER DUET, CH DE 24 VERSAILLES; Harriet CORVOL, AP-HP-Trousseau; Laure COSSON, CHU DE TOURS-25

1 Clocheville; Isabelle DANNER BOUCHER, CHU DE NANTES; Sandra de MIRANDA, HOPITAL FOCH; Eric DENEUVILLE, CHU DE RENNES-Hôpital sud; David 2 DRUMMOND, AP-HP-Necker; Jean-Christophe DUBUS, AP-HM; Isabelle DURIEU, 3 4 HOSPICES CIVILS DE LYON-Groupe hospitalier sud; Ralph EPAUD, CHI DE CRETEIL; Michèle GERARDIN, AP-HP-Robert Debré; Dominique GRENET, HOPITAL 5 FOCH; Véronique HOUDOUIN, AP-HP-Robert Debré; Frédéric HUET, CHU DE DIJON; 6 Reem KANAAN, AP-HP-Cochin; Romain KESSLER, HOPITAUX UNIVERSITAIRES 7 DE STRASBOURG; Alice LADAURADE, CHU DE BESANCON; Jeanne LANGUEPIN, 8 CHU DE LIMOGES; Muriel LAURANS, CHU DE CAEN; Olivier Le ROUZIC, CHU DE 9 LILLE; Sylvie LEROY, CHU DE NICE; Cathie LLERENA, CHU DE GRENOBLE; Julie 10 MACEY, CHU DE BORDEAUX-Haut-Lévêque; Julie MANKIKIAN, CHU DE TOURS-11 Bretonneau; Christophe MARGUET, CHU DE ROUEN; Clémence MARTIN, AP-HP-12 Cochin; Laurent MELY, HOSPICES CIVILS DE LYON-Renée Sabran; Marie 13 MITTAINE, CHU DE TOULOUSE-Hôpital des enfants; Marlène MURRIS-ESPIN, CHU 14 DE TOULOUSE-Hôpital Larrey; Caroline PERISSON, CHU DE LA REUNION-Hôpital 15 sud; Anne PREVOTAT, CHU DE LILLE; Sophie RAMEL, FONDATION ILDYS 16 (Roscoff); Cinthia RAMES, CHU D'AMIENS; Philippe REIX, HOSPICES CIVILS DE 17 LYON-Hôpital femme mère enfant; Marine REVILLION, CHU DE LILLE; Martine 18 REYNAUD-GAUBERT, AP-HM; Bénédicte RICHAUD-THIRIEZ, CHU DE BESANCON; 19 Manuëla SCALBERT-DUJARDIN, CH DE DUNKERQUE; 20 Isabelle SERMET-GAUDELUS, AP-HP-Necker; Véronique STORNI, CH BRETAGNE ATLANTIQUE; 21 Aurélie TATOPOULOS, CHU DE NANCY; Guillaume THOUVENIN, AP-HP-Trousseau; 22 Francoise TROUSSIER, CHU D'ANGERS; Laurence WEISS. HOPITAUX 23 UNIVERSITAIRES DE STRASBOURG; Nathalie WIZLA, CHU DE LILLE. 24

Funding: This work was supported by the Association Vaincre La Mucoviscidose and Filière
 de Santé Maladies rares Muco-CFTR. These funders had no role in the conduct or reporting
 of this study.

Conflicts of Interest: CM reports consulting fees from Vertex unrelated to this work; 4 5 payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events for the Viatris symposia 2021 and Zambon symposia 2021; support for 6 attending meetings and/or travel from Zambon for ECFS 2019 and JFM (French CF 7 meeting); participation on a Data Safety Monitoring Board or Advisory Board for Vertex 8 (institutional fees) and Zambon (personal fees); and an unpaid position as the Head of the 9 French CF society. PRB reports grants or contracts unrelated to this work and paid to the 10 author's institution from GSK and Vertex; consulting fees from Astra-Zeneca, Chiesi, GSK, 11 Insmed, and Vertex; personal fees for lectures from Astra-Zeneca, Boehringer Ingelheim, 12 13 Chiesi, GSK, Novartis,

Pfizer, Vertex, Viatris, and Zambon; and support for attending meetings and/or travel from
Astra-Zeneca, Zambon, and Viatris. The authors have no other actual or potential conflicts of
interest to declare.

1 **References**

2	1.	https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases.
3	2.	Vaincre-la-Mucoviscidose. Registre Français de la mucoviscidose - Bilan des données
4		2019. 2021.
5	3.	Elborn JS. Cystic fibrosis. Lancet 2016 ; 388(10059): 2519-31.
6	4.	Martin C, Hamard C, Kanaan R, et al. Causes of death in French cystic fibrosis
7		patients: The need for improvement in transplantation referral strategies! J Cyst
8		Fibros 2016 ; 15(2): 204-12.
9	5.	Viviani L, Assael BM, Kerem E, group EHNs. Impact of the A (H1N1) pandemic
10		influenza (season 2009-2010) on patients with cystic fibrosis. J Cyst Fibros 2011;
11		10(5): 370-6.
12	6.	Corvol H, de Miranda S, Lemonnier L, et al. First Wave of COVID-19 in French
13		Patients with Cystic Fibrosis. J Clin Med 2020; 9(11).
14	7.	Cosgriff R, Ahern S, Bell SC, et al. A multinational report to characterise SARS-
15		CoV-2 infection in people with cystic fibrosis. J Cyst Fibros 2020; 19(3): 355-8.
16	8.	McClenaghan E, Cosgriff R, Brownlee K, et al. The global impact of SARS-CoV-2 in
17		181 people with cystic fibrosis. J Cyst Fibros 2020; 19(6): 868-71.
18	9.	Naehrlich L, Orenti A, Dunlevy F, et al. Incidence of SARS-CoV-2 in people with
19		cystic fibrosis in Europe between February and June 2020. J Cyst Fibros 2021; 20(4):
20		566-77.
21	10.	Colombo C, Cipolli M, Daccò V, et al. Clinical course and risk factors for severe
22	Y	COVID-19 among Italian patients with cystic fibrosis: a study within the Italian
23		Cystic Fibrosis Society. Infection 2021: 1-9.
24	11.	Jung A, Orenti A, Dunlevy F, et al. Factors for severe outcomes following SARS-
25		CoV-2 infection in people with cystic fibrosis in Europe. ERJ Open Res 2021; 7(4).

1	12.	Mondejar-Lopez P, Quintana-Gallego E, Giron-Moreno RM, et al. Impact of SARS-
2		CoV-2 infection in patients with cystic fibrosis in Spain: Incidence and results of the
3		national CF-COVID19-Spain survey. Respir Med 2020; 170: 106062.
4	13.	Caruso D, Zerunian M, Polici M, et al. Chest CT Features of COVID-19 in Rome,
5		Italy. Radiology 2020 : 201237.
6	14.	Caro-Dominguez P, Shelmerdine SC, Toso S, et al. Thoracic imaging of coronavirus
7		disease 2019 (COVID-19) in children: a series of 91 cases. Pediatr Radiol 2020;
8		50(10): 1354-68.
9	15.	Nathan N, Prevost B, Corvol H. Atypical presentation of COVID-19 in young infants.
10		Lancet 2020 ; 395(10235): 1481.
11	16.	Nathan N, Prevost B, Sileo C, et al. The Wide Spectrum of COVID-19 Clinical
12		Presentation in Children. J Clin Med 2020; 9(9).
13	17.	Mathew HR, Choi MY, Parkins MD, Fritzler MJ. Systematic review: cystic fibrosis in
14		the SARS-CoV-2/COVID-19 pandemic. BMC pulmonary medicine 2021 ; 21(1): 173.
15	18.	Burgel PR, Goss C. COVID-19 outcomes in people with cystic fibrosis. Curr Opin
16		Pulm Med 2021 ; 27(6): 538-43.
17	19.	Gaythorpe KAM, Bhatia S, Mangal T, et al. Children's role in the COVID-19
18		pandemic: a systematic review of early surveillance data on susceptibility, severity,
19		and transmissibility. Sci Rep 2021; 11(1): 13903.
20	20.	Bain R, Cosgriff R, Zampoli M, et al. Clinical characteristics of SARS-CoV-2
21		infection in children with cystic fibrosis: An international observational study. J Cyst
22	Y	Fibros 2020 .
23	21.	Benn CS, Netea MG, Selin LK, Aaby P. A small jab - a big effect: nonspecific
24		immunomodulation by vaccines. Trends Immunol 2013 ; 34(9): 431-9.

1	22.	Zimmermann P, Curtis N. Coronavirus Infections in Children Including COVID-19:
2		An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and
3		Prevention Options in Children. Pediatr Infect Dis J 2020; 39(5): 355-68.
4	23.	Bucher J, Boelle PY, Hubert D, et al. Lessons from a French collaborative case-
5		control study in cystic fibrosis patients during the 2009 A/H1N1 influenza pandemy.
6		BMC Infect Dis 2016 ; 16: 55.
7	24.	Kieninger E, Singer F, Tapparel C, et al. High rhinovirus burden in lower airways of
8		children with cystic fibrosis. Chest 2013 ; 143(3): 782-90.
9	25.	Somayaji R, Goss CH, Khan U, Neradilek M, Neuzil KM, Ortiz JR. Cystic Fibrosis
10		Pulmonary Exacerbations Attributable to Respiratory Syncytial Virus and Influenza:
11		A Population-Based Study. Clin Infect Dis 2017; 64(12): 1760-7.
12	26.	van Ewijk BE, Wolfs TF, Fleer A, Kimpen JL, van der Ent CK. High Pseudomonas
13		aeruginosa acquisition rate in CF. Thorax 2006; 61(7): 641-2.
14	27.	Ruffin M, Bigot J, Calmel C, et al. Flagellin From Pseudomonas aeruginosa
15		Modulates SARS-CoV-2 Infectivity in Cystic Fibrosis Airway Epithelial Cells by
16		Increasing TMPRSS2 Expression. Front Immunol 2021; 12: 714027.
17	28.	Belsky JA, Tullius BP, Lamb MG, Sayegh R, Stanek JR, Auletta JJ. COVID-19 in
18		immunocompromised patients: A systematic review of cancer, hematopoietic cell and
19		solid organ transplant patients. J Infect 2021; 82(3): 329-38.
20	29.	Corvol H, Alimi A, Prevost B, et al. Atypical severe organizing pneumonia following
21		COVID-19 in an immunocompromised teenager. Clin Infect Dis 2021.
22	30.	Kates OS, Haydel BM, Florman SS, et al. Coronavirus Disease 2019 in Solid Organ
23		Transplant: A Multicenter Cohort Study. Clin Infect Dis 2021; 73(11): e4090-e9.
24	31.	Southern KW, Barker PM, Solis-Moya A, Patel L. Macrolide antibiotics for cystic
25		fibrosis. The Cochrane database of systematic reviews 2012; 11: CD002203.

- 1 32. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a 2 treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J 3 Antimicrob Agents **2020**; 56(1): 105949.
- 4 33. Schogler A, Kopf BS, Edwards MR, et al. Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells. Eur Respir J 2015; 45(2): 428-39. 5
- Albani F, Fusina F, Giovannini A, et al. Impact of Azithromycin and/or 6 34. Hydroxychloroquine on Hospital Mortality in COVID-19. J Clin Med 2020; 9(9). 7
- 35. Meseguer Barros CM, Alzueta Isturiz N, Sainz de Rozas Aparicio R, et al. Sars-Cov-2 8 Infection in Patients on Long-Term Treatment with Macrolides in Spain: A National 9 Cross-Sectional Study. Antibiotics 2021; 10(9).
- Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal 36. 11 expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983; 12
- 127(6): 725-34. 13

13-21.

- Rolland-Cachera MF, Cole TJ, Sempé M, Tichet J, Rossignol C, Charraud A. Body 37. 14
- Mass Index variations: centiles from birth to 87 years. Eur J Clin Nutr 1991; 45(1): 15
- 16

10

1 Tables

2 Table 1. COVID-19 cases in people with cystic fibrosis (pwCF) as compared with the

3 overall French CF populatio	3	overall	French	CF	popu	latio
--------------------------------------	---	---------	--------	----	------	-------

	pwCF diagnosed	Remaining pwCF	
	with SARS-CoV-2	from the French CF	P-value
	infection	registry [2]	
	n = 223	n = 6924	う >
Male, n (%)	110 (49.3)	3618 (52.3)	0.39
Age (years), median (range: min-max)	29.3 (0-69)	21.6 (0.6-85.1)	<0.0001
Children (<18 years-old), n (%)	48 (21.5)	2832 (40.9)	<0.0001
Exocrine pancreatic insufficiency, n (%)	196 (87.9)	5555 (80.2)	0.023
Post-transplant, n (%)	61 (27.4)	853 (12.3)	<0.0001
CFTR mutations	~		
F508del homozygotes, %	95 (42.6)	2831 (40.9)	0.22
F508del heterozygotes, %	100 (44.8)	2919 (42.2)	
Other	28 (12.6)	1174 (17)	
Lung function, ppFEV ₁ ⁽¹⁾			
median (range: min-max)	77.6 (22.3-129.6)	83.9 (15.2-164.4)	<0.0001
<40%, n (%)	23 (10.3)	420 (6.1)	0.01
[40-70%[, n (%)	64 (28.7)	1417 (20.5)	
>=70%, n (%)	126 (56.5)	3997 (57.7)	
Nutritional status, BMI Z-score ⁽²⁾			
median (range: min-max)	-0.3 (-2.7-4.6)	-0.3 (-7.5-14.11)	0.57
Comorbidities			
ABPA, n (%)	29 (13)	588 (8.5)	0.01
CF liver disease, n (%)	45 (20.2)	1107 (16)	0.09
CF related diabetes, n (%)	77 (34.5)	1401 (20.2)	<0.0001
Treatments prior SARS-Cov-2 infection			
Inhaled corticosteroids, n (%)	121 (54.3)	3612 (52.2)	0.54
Oral corticosteroids (> 3 months), n (%)	54 (24.2)	890 (12.9)	<0.0001
Azithromycin, n (%)	115 (51.6)	2458 (35.5)	<0.0001
CFTR Modulators, n (%)	68 ⁽³⁾ (30.5)	1591 (23)	0,009
Long-term oxygen therapy (> 3 months), n (%)	20 (9)	305 (4.4)	0.001
Long-term non-invasive ventilation (> 3 months), n (%)	16 (7.2)	314 (4.5)	0.06

4 ⁽¹⁾Knudson equations [36]; ⁽²⁾Rolland-Cachera equations [37]; ⁽³⁾12 ivacaftor; 42 lumacaftor-ivacaftor;

5 22 elexacaftor-tezacaftor-ivacaftor (8 patients had 2 CFTR modulators).

6 *Abbreviations:* pwCF, people with cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance

7 regulator; ppFEV₁, percent predicted forced expiratory volume in 1 s; BMI, body mass index; ABPA,

8 allergic bronchopulmonary aspergillosis.

1 Table 2. Non-transplanted vs. post-transplant people with cystic fibrosis (pwCF) at

	Non-	Doct transplant	
	transplanted	Post-transplant	
	n = 162	n = 61	P-value
Male, n (%)	81 (50)	29 (47.5)	0.77
Age (years), median (range: min-max)	26.0 (0-69)	34.1 (13-63)	<0.0001
Exocrine pancreatic insufficiency, n (%)	137 (84.6)	59 (96.7)	0.01
CFTR mutations			0.71
F508del homozygotes, n (%)	66 (40.7)	29 (47.5)	
F508del heterozygotes, n (%)	75 (46.3)	25 (41)	
Other	21 (13)	7 (11.5)	
Influenza vaccine in the past 12 months, n (%)	92 (56.8)	26 (42.6)	0.07
ppFEV1 ⁽¹⁾ , median (range: min-max)	72.2 (22.3-129.6)	83.7 (24.3-113.8)	0.07
BMI Z-score ⁽²⁾ , median (range: min-max)	-0.1 (-2-4.6)	-0.6 (-2.7-1.9)	0.0004
Chronic infection by Pseudomonas		16 (26.2)	.0.0001
aeruginosa in past 12 months, n (%)	76 (46.9)	16 (26.2)	<0.0001
Comorbidities	K K '		
ABPA, n (%)	24 (14.8)	5 (8.2)	0.1
CF liver disease, n (%)	33 (20.4)	12 (19.7)	0.86
CF related diabetes, n (%)	37 (22.8)	40 (65.6)	<0.0001
Systemic arterial hypertension, n (%)	5 (3.1)	23 (37.7)	<0.0001
Treatments prior SARS-Cov-2 infection			
Inhaled corticosteroids, n (%)	94 (58)	18 (29.5)	<0.0001
Oral corticosteroids, n (%)	8 (4.9)	43 (70.5)	<0.0001
CFTR Modulators ⁽³⁾ , n (%)	68 (42)	0	NA ⁽³⁾
Azithromycin, n (%)	65 (40.1)	36 (59)	0.04

2 SARS-CoV-2 infection onset

3

4 ⁽¹⁾Knudson equations [36]; ⁽²⁾Rolland-Cachera equations [37]; ⁽³⁾NA: not appropriate as
5 CFTR modulators are not indicated in post-transplant patients.

Abbreviations: pwCF, people with cystic fibrosis; CFTR, cystic fibrosis transmembrane
conductance regulator; ppFEV₁, percent predicted forced expiratory volume in 1 s; BMI,
body mass index; ABPA, allergic bronchopulmonary aspergillosis.

1 Table 3. COVID-19 severity and outcomes of non-transplanted vs. post-transplant

2 people with cystic fibrosis (pwCF)

	All	Non-	Post-	Non-transplanted
	pwCF	transplanted	transplant	vs post-transplan
	n = 223	n = 162	n = 61	P-value
Patients' management				<0.0001
Ambulatory care, n (%)	163 (73.1)	133 (82.1)	30 (49.2)	
Hospitalization, n (%)	60 (26.9)	29 (17.9)	31 (50.8)	
Hospitalization setting				<0.0001
Medical ward (non-ICU), n (%)	46 (20.6)	27 (16.7)	19 (31.1)	
ICU, n (%)	14 (6.3)	2 (1.2)	12 (19.7)	
Hospitalization duration (days), median (range)	10.5 (1-72)	6 (1-40)	15 (3-72)	<0.0001
Patient discharge, n (%)				<0.0001
<10 days, n (%)	26 (11.7)	18 (11.1)	8 (13.1)	
10–19 days, n (%)	22 (9.9)	9 (5.6)	13 (21.3)	
20–29 days, n (%)	7 (3.1)	0	7 (11.5)	
>30 days, n (%)	5 (2.2)	1 (0.6)	4 (6.6)	
Respiratory support				
Additional oxygen therapy, n (%)	23 (10.3)	7 (4.3)	16 (26.2)	<0.0001
Non-invasive ventilation (BIPAP, CPAP), n (%)	1 (0.4)	1 (0.6)	0	
High flow nasal canula oxygen therapy, n (%)	8 (3.6)	2 (1.2)	6 (9.8)	<0.0001
Invasive Ventilation, n (%)	2 (0.9)	0	2 (3.3)	0.07
ECMO	0	0	0	
Additional treatments				
Additional IV antibiotics, n (%)	36 (16.1)	18 (11.1)	18 (29.5)	<0.0001
Additional oral antibiotics, n (%)	63 (28.3)	51 (31.5)	12 (19.7)	0.09
Additional Azithromycin, n (%)	8 (3.6)	6 (3.7)	2 (3.3)	1
Additional systemic corticosteroids, n (%)	28 (12.6)	6 (3.7)	22 (36.1)	<0.0001
Hydroxychloroquine, n (%)	2 (0.9)	0	2 (3.3)	0.07

Sarilumab, n (%)	4 (1.8)	0	4 (6.6)	<0.0001
Respiratory complications	40 (17.9)	27 (16.7)	13 (21.3)	0.44
Respiratory exacerbation, n (%)	32 (14.3)	25 (15.4)	7 (11.5)	0.53
Bacterial pneumonia, n (%)	8 (3.6)	3 (1.9)	5 (8.2)	0.037
ARDS, n (%)	5 (2.2)	0	5 (8.2)	<0.0001
Hemoptysis, n (%)	3 (1.3)	1 (0.6)	2 (3.3)	0.18
Overall evolution				X í
Recovered without short-term sequelae, n (%)	204 (91.5)	149 (92)	55 (90.2)	0.79
Unknown / possible sequelae to follow, n (%)	16 (13)			
Died, n (%)	3 (1.3)	0	3 (4.9)	0.02
1			2	

2 Abbreviations: ARDS, acute respiratory distress syndrome; BIPAP, bilevel positive airway

3 pressure; CPAP, continuous positive airway pressure; ECMO, extracorporeal membrane

4 oxygenation; IV, intravenous

	Non-transplanted pwCF			Post-transplant pwCF			
	Severe	Non severe	OR [95% CI]	Severe	Non severe	OR [95% CI]	
Number of pwCF, n (%)	13 (8)	149 (92)		21 (35)	40 (65)		
Clinical characteristics							
Male, n (%)	5 (38.5)	76 (51.0)	0.6 [0.19-1.92]	8 (38.1)	21 (52.5)	0.56 [0.19-1.64]	
Age (years), median (range: min-max)	29.7 (0.6-44.3)	25.9 (0-69)	1.01 [0.96-1.05]	34.1 (12.5-48.1)	32.8 (16.6-63.4)	0.99 [0.94-1.04]	
Exocrine pancreatic insufficiency, n (%)	12 (92.3)	125 (83.9)	2.3 [0.29-18.53]	19 (90.5)	40 (100)	NA	
F508del homozygotes, n (%)	4 (30.8)	62 (41.6)	0.62 [0.18-2.1]	8 (38.1)	21 (52.5)	0.56 [0.19-1.64]	
ppFEV1 ⁽¹⁾ , median (range: min-max)	54.6 (23.3-71.8)	75.1 (22.3-129.6)	1.04 [1.01-1.08]	90 (27.2-113.8)	82.2 (24.3-106.3)	1 [0.97-1.02]	
BMI Z-score ⁽²⁾ , median (range: min-max)	-0.3 (-1.4-3.9)	-0.1 (-2-4.6)	0.87 [0.52-1.46]	-0.5 (-2.3-0.4)	-0.6 (-2.7-1.9)	1.02 [0.56-1.84]	
Comorbidities							
ABPA, n (%)	2 (15.4)	22 (14.8)	1.04 [0.22-4.92]	2 (9.5)	3 (7.5)	1.3 [0.2-8.46]	
CF liver disease, n (%)	4 (30.8)	29 (19.5)	1.84 [0.53-6.39]	4 (19)	8 (20.0)	0.94 [0.25-3.58]	
CF related diabetes, n (%)	6 (46.2)	31 (20.8)	3.26 [1.02-10.4]	13 (61.9)	27 (67.5)	0.78 [0.26-2.35]	
Treatments prior SARS-CoV-2							
infection							
Inhaled corticosteroids, n (%)	9 (69.2)	94 (63.1)	1.32 [0.39-4.49]	9 (42.9)	9 (22.5)	2.58 [0.83-8.06]	
Oral corticosteroids, n (%)	2 (15.4)	9 (6.0)	2.83 [0.54-14.74]	15 (71.4)	28 (70.0)	1.07 [0.33-3.43]	

Table 4. Risk factors for COVID-19 severity in non-transplanted and post-transplant people with cystic fibrosis (pwCF)

CFTR Modulators, n (%)	4 (30.8)	64 (43,0)	0.59 [0.17-2.0]	0 (0)	0 (0)	NA ⁽³⁾
Azithromycin, n (%)	6 (46.2)	73 (49.0)	0.89 [0.29-2.77]	14 (66.7)	22 (55.0)	1.64 [0.55-4.93]
1						

- 2 ⁽¹⁾Knudson equations [36]; ⁽²⁾Rolland-Cachera equations [37]; ⁽³⁾NA: not appropriate as CFTR modulators are not indicated in post-transplant patients.
- 3 *Abbreviations:* pwCF, people with cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; ppFEV₁, percent-predicted forced expiratory
- 4 volume in 1 s; BMI, body mass index; ABPA, allergic bronchopulmonary aspergillosis.

C

1 Figure legends

Figure 1. Incidence during the first year of the COVID-19 pandemic (March 2020 to
April 2021) in adults (non-transplanted and post-transplant) and children with cystic
fibrosis (CF). These figures depicts the evolution in (A) the overall number of cases, and (B)
the number of severe cases. The scatter with smooth lines graphs (A) and the histograms (B)
were generated using Microsoft Excel®.

- *Figure 2.* Distribution of the main symptoms at SARS-CoV-2 infection onset in
 people with cystic fibrosis (pwCF) according to transplantation status.
- 9






Figure 1 160x226 mm (0.4 x DPI)




Figure 2 160x226 mm (0.4 x DPI)